{"links":{"html":"https://www.erudio.com/reports/starlit-nct06574880","json":"https://www.erudio.com/reports/starlit-nct06574880.json","markdown":"https://www.erudio.com/reports/starlit-nct06574880.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"starlit-06574880"}},"request":"https://www.erudio.com/contact?report=starlit-06574880"},"offer":{"cited_commentary_sources":3,"verified_hcp_statements":64,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":7,"optional":true,"price_per_verified_person_usd":15,"price_usd":105,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"starlit-nct06574880"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=starlit-06574880","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/starlit-nct06574880","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T17:33:41.469086Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description. The trial's name is spelled as its investigators write it, “STARLiT” (NCT06574880), outside quotations (was “STARLIT”)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Phase II: Androgen deprivation therapy (ADT)-free survival"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":3,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":1,"title":"PSMA staging, occult disease and atypical uptake"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":1,"title":"Nodal treatment and endocrine-intensification alternatives"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":1,"title":"PET–MRI target definition and local dose personalization"},{"claim_count":10,"coverage":"discussed","id":"A4","source_count":1,"title":"Access, fractionation and research versus routine care"},{"claim_count":7,"coverage":"discussed","id":"A5","source_count":1,"title":"Margins, localization, monitoring and spacers"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":1,"title":"Country-specific imaging economics and diagnostic radiation exposure"},{"claim_count":2,"coverage":"discussed","id":"A7","source_count":1,"title":"Unnamed SBRT–Lu-177-PSMA-617 safety endorsement and advanced-disease ADT-impact hopes"}],"counts":{"cited_sources":4,"claims_by_expression_type":{"comparison":3,"experience":14,"interpretation":7,"opinion":12,"primary_context":2,"question":7,"restatement":8,"uncertainty":2,"unspecified":9},"claims_by_kind":{"protocol_statement":2,"source_observation":62},"clinician_statements":17,"evidence_units":46,"findings":8,"people_cited":7,"people_identity_verified":7,"people_total":7,"screened_sources":12,"verified_claims":64},"findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":4,"views":3},"has_counterview":true,"limitations":3,"links":{"context":2,"support":8},"ma_question":true,"named_voices":4,"passages":8,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"ADT replacement attracts interest as a research strategy, not an established treatment option"},{"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"An unnamed combination-safety endorsement must not become a STARLiT safety conclusion"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":0,"views":1},"has_counterview":true,"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":2,"passages":6,"sources":1,"sources_by_kind":{"media":1}},"title":"PSMA-positive nodes motivate systemic and regional escalation in one practice, with explicit evidentiary limits"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":3,"questions":2,"restated":0,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":3,"passages":7,"sources":1,"sources_by_kind":{"media":1}},"title":"PSMA staging changes treatment decisions, but negative scans and stage migration limit interpretation"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":3,"views":4},"has_counterview":false,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":4,"passages":8,"sources":1,"sources_by_kind":{"media":1}},"title":"PET–MRI complementarity supports dose personalization, but better delineation is not proven clinical benefit"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":3,"questions":0,"restated":4,"views":3},"has_counterview":true,"limitations":4,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":8,"sources":1,"sources_by_kind":{"media":1}},"title":"High-risk SBRT use is qualified by research availability, attendance constraints and patient preference"},{"id":"F7","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":7,"sources":1,"sources_by_kind":{"media":1}},"title":"Localization, margins and spacer decisions remain equipment- and operator-dependent"},{"id":"F8","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":5,"views":1},"has_counterview":false,"limitations":3,"links":{"context":2,"support":11},"ma_question":true,"named_voices":3,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Quality-of-life and economic value remain questions about treatment consequences, not scan price alone"}],"medical_affairs_question":"What evidence of cancer control, sustained ADT avoidance and patient-reported benefit would justify substitution rather than the escalation described here?","sections":{"analysis":[{"id":"section-1","level":2,"title":"ADT replacement is the attraction—and remains the experiment"},{"id":"section-2","level":2,"title":"The unnamed safety endorsement is context, not STARLiT evidence"},{"id":"section-3","level":2,"title":"PSMA-positive nodes can lead toward more systemic treatment"},{"id":"section-4","level":2,"title":"More informative staging does not remove occult-disease uncertainty"},{"id":"section-5","level":2,"title":"Better target definition leaves the benefit of dose personalization open"},{"id":"section-6","level":2,"title":"Access and patient circumstances qualify enthusiasm for high-risk SBRT"},{"id":"section-7","level":2,"title":"Delivery choices are not interchangeable across centers"},{"id":"section-8","level":2,"title":"Value depends on patient outcomes and what follows the scan"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1}],"id":"T1","label":"Primary endpoint: Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T2","label":"Primary endpoint: Phase II: Androgen deprivation therapy (ADT)-free survival"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T17:33:41.469086Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T17:46:12Z","record_hash":"3871493605ae5020470e143ae3d05c934f47c391e8cf718401422c857f86c5e0","release_hash":"1f41364d04d2f551c4fe35de7d331389098b1f1cd8840f76138a00750d107cf5","report_id":"erudio-nct06574880","run_id":"dc12532d-2d64-473c-9c38-a5c8d1fb0385","schema_version":"5.0","slug":"starlit-06574880","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"STARLiT asks whether Lu-PSMA-617 combined with stereotactic body radiotherapy can replace androgen-deprivation therapy for locally advanced prostate cancer. Commentary comes from X posts and a podcast with radiation oncologists, including one described on the episode as a principal investigator of STARLiT. The discussion turns on whether ADT replacement can move beyond research, and how research availability, attendance constraints and patient preferences shape SBRT use in high-risk prostate cancer.","meta_description":"12 sources screened · 64 verified statements (17 from clinicians verified by NPI or staff page) from 4 sources · 8 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-c400e3a942678fd4c5b9","claim-723e6a9e83d37d4527d2"],"id":"F1","paraphrase":"A radiation oncologist, described on the podcast as a STARLiT principal investigator, sets out the question of replacing ADT with radioligand therapy alongside definitive radiotherapy.","source_channel":"podcast","source_date":"2025-01-15","title":"ADT replacement attracts interest as a research strategy, not an established treatment option"},{"cited_claim_ids":["claim-705954357fda9f03e7a2","claim-723e6a9e83d37d4527d2"],"id":"F6","paraphrase":"A radiation oncologist on the podcast asks about use of an alternative prostate radiotherapy schedule.","source_channel":"podcast","source_date":"2025-01-15","title":"High-risk SBRT use is qualified by research availability, attendance constraints and patient preference"}]},"publication":{"approved_at":"2026-10-30T17:46:12Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-30T23:48:20Z","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description. The trial's name is spelled as its investigators write it, “STARLiT” (NCT06574880), outside quotations (was “STARLIT”)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":12},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition do not represent all HCPs or all public discussion; additional relevant views may be absent.","Some short passages were not fully assessed, and one additional potentially relevant source was not read. References that do not name the trial or use different wording may also be missing.","No full study protocol or exact-trial results publication was identified. Registry methods and presentation objectives cannot establish observed treatment benefit or safety.","The available material does not establish regulatory authorization for this use.","The trial-unnamed February X exchange does not establish which study supplied its safety data or whether its advanced-disease discussion matches STARLiT's population.","Local practice, access restrictions and adoption forecasts reflect their source timing and settings; they should not be read as current or universal policies.","A speaker's principal-investigator involvement and the presenter's involvement are descriptions made by the sources, not independently established trial roles.","Not yet captured in this edition: a question about future integration and universal adoption of SBRT and PSMA PET.","Not yet captured in this edition: a view on biological testing to identify patients most likely to benefit from treatment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":2,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":3,"methods":1},"count":4,"evidence_window":{"end":"2025-09-30","start":"2025-01-15"},"retrieval_snapshot":"2026-10-30T16:20:12.326579Z","timeline":[{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W40"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06574880:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06574880:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-a7oganv7to523qazligxhkid-3lkveq5egvv2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogjf45goezwuy4f2xoxgik66-3m4jbsyliwj2g","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:852a80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890393664439943597:34116f47-a539-48d2-9c07-9e79d9b9c047","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1936926006872338870:6d981a61-8396-4612-8fe3-00ef9508ef55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943760000104464390:cfa4e41e-0dcd-4dac-b843-e6603609d011","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972085552657908109:4d9fa463-d985-4827-a4e3-4908b0877c02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973115697141014642:eb3df908-ddc5-492d-874a-467f0c806781","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973432852403400936:5eca1a68-b941-4fe2-b6bb-2222e8349efb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979910575829176677:695f0cd1-c5c1-46ca-8eff-4aca700332c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103134652630274156:e0e152c4-ba64-4da3-bf2e-f4797cc2ad06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105311915597496379:44183c4d-9897-481a-8f77-03fbaea59efa","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-09-30","start":"2025-01-15"},"retrieval_snapshot":"2026-10-30T16:20:12.326579Z","timeline":[{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W39"},{"count":2,"week":"2025-W40"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: lu-psma-617","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Malignant Neoplasm of Prostate","status":"unmapped"},{"reason":"Unmapped registry condition: Locally Advanced Prostate Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"STARLiT","aliases":["STARLiT","STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial"],"brief_title":"STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Malignant Neoplasm of Prostate","Locally Advanced Prostate Cancer"],"display_condition":"locally advanced prostate cancer","display_interventions":[["Lu-PSMA-617","SBRT"]],"enrollment":{"count":45,"type":"ESTIMATED"},"interventions":[{"name":"Lu-PSMA-617","synonyms":["Pluvicto"],"type":"DRUG"},{"name":"5-fraction Stereotactic Body Radiation Therapy (SBRT)","synonyms":["SBRT"],"type":"RADIATION"}],"nct_id":"NCT06574880","official_title":"STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-09-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"The Phase I goal is to determine the maximally tolerated dose (MTD) of Lu-PSMA-617 when administered with prostate SBRT treatment. The MTD will be captured by analyzing the incidence of dose limiting toxicities occurring within the four weeks after the last dose of treatment.","measure":"Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617","timeFrame":"4 weeks after final dose of treatment (treatment expected to last up to six months)"},{"description":"The Phase II goal is to determine the 3-year rate of ADT-free survival.","measure":"Phase II: Androgen deprivation therapy (ADT)-free survival","timeFrame":"3 years post treatment"}],"registered_date":{"date":"2024-08-28","type":"ACTUAL"},"registry_last_updated":"2026-05-26","registry_url":"https://clinicaltrials.gov/study/NCT06574880","short_name":"STARLiT","short_name_basis":"registry_acronym","sponsor":"Angela Y. Jia, MD PhD","start_date":{"date":"2025-05-13","type":"ACTUAL"},"study_design":"interventional, na, single group, phase1, phase2","study_ids":[{"id":"CASE7824","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}